title: Regulation of leptin release and lipolysis by PGE2 in rat adipose tissue.
abstract: The role of eicosanoids formed by adipose tissue from rats was examined in the presence of the specific cyclooxygenase-2 inhibitor NS-398. This agent totally blocked the release of prostaglandin E2 (PGE2) by rat adipose tissue over a 24-h incubation in primary culture. The final concentration of PGE2 after 24 h was 12 nM, and half-maximal inhibition of PGE2 formation required 35 nM NS-398. While inhibition of PGE2 formation by NS-398 had no effect on basal leptin release or lipolysis, it enhanced the lipolytic action of 10 nM isoproterenol by 36%. The in vivo administration of PGE2 doubled serum leptin. PGE2 also directly stimulated leptin release by rat adipose tissue incubated in the presence of 25 nM dexamethasone, which inhibited endogenous PGE2 formation by 94%. The inhibition of lipolysis as well as the stimulation of leptin release by PGE2 were mimicked by N6-cyclopentyladenosine (CPA). These data indicate that exogenous PGE2 can stimulate leptin release by adipose tissue when the basal formation of PGE2 is blocked by dexamethasone. However, while the endogenous formation of PGE2 does not appear to regulate basal lipolysis or leptin release, it may play a role in the activation of lipolysis by catecholamines.
authors.affiliation: Department of Biochemistry, College of Medicine, University of Tennessee, Memphis 38163, USA. jfain@utmem.edu
authors.forename: J N
authors.initials: JN
authors.lastname: Fain
authors.forename: C W
authors.initials: CW
authors.lastname: Leffler
authors.forename: S W
authors.initials: SW
authors.lastname: Bahouth
authors.forename: A M
authors.initials: AM
authors.lastname: Rice
authors.forename: S A
authors.initials: SA
authors.lastname: Rivkees
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology / Q000502:physiology*; D006706:Homeostasis; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D020738:Leptin / Q000378:metabolism*; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D009578:Nitrobenzenes / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D020738:Leptin; D009578:Nitrobenzenes; D013449:Sulfonamides; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; C048599:N(6)-cyclopentyladenosine; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D000241:Adenosine; D015232:Dinoprostone